SCHEMBL30862836

SCHEMBL30862836

CC(=O)N1CCN(c2c3n(c4nc(C5=CCOCC5)nn4c2=O)[C@@H](C(=O)Nc2ccc(C(F)(F)F)cc2)CC3)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.46
▸ FPR2 P25090 1/20 0.36
▸ EPHX2 P34913 5/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ MTOR P42345 1/20 0.36
▸ MAPT P10636 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ TRPV1 Q8NER1 3/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ USP2 O75604 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ NR3C1 P04150 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ JAK2 O60674 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27386392 1.00 WRN (0.46) WRNFPR2EPHX2PIK3CAMTOR
SCHEMBL30862692 0.92 WRN (0.44) WRNEPHX2PIK3CAMTORMAPT
SCHEMBL30862758 0.92 WRN (0.44) WRNEPHX2PIK3CAMTORMAPT
SCHEMBL30862847 0.90 WRN (0.41) WRNEPHX2PIK3CAMTORMAPT
SCHEMBL30862683 0.90 WRN (0.41) WRNEPHX2PIK3CAMTORMAPT
SCHEMBL30862713 0.90 WRN (0.41) WRNEPHX2PIK3CAMTORMAPT
SCHEMBL27386869 0.88 WRN (0.48) WRNEPHX2PIK3CAMTORMAPT
SCHEMBL27386868 0.88 WRN (0.48) WRNEPHX2PIK3CAMTORMAPT
SCHEMBL27386390 0.88 WRN (0.48) WRNEPHX2PIK3CAMTORMAPT
SCHEMBL31601630 0.86 WRN (0.40) WRNPIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601746-A1 TRICYCLIC COMPOUNDS AND THEIR USES Novartis AG (CH) 2025-08-20 — — EP disclosed
CN-120077048-A Tricyclic compounds and uses thereof 诺华股份有限公司 2025-05-30 — — CN disclosed
US-20240245694-A1 Tricyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-07-25 — — US disclosed
WO-2024079623-A1 TRICYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245694-A1 Tricyclic Compounds and their Uses F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R WRN 2992/4885FPR2 2148/4885EPHX2 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback